Efficacy and safety of adding bevacizumab biosimilar or original drug to platinum-based chemotherapy as first-line treatment in patients with advanced NSCLC: a systematic review and meta-analysis.

Liu YangMaobai LiuXueqiong CaoNa LiBin ZhengJianhao DengHongfu Cai

Published in: Therapeutic advances in medical oncology (2022)

The efficacy and safety of bevacizumab biosimilars in the treatment of advanced non-squamous NSCLC are highly similar to those of the original drug combined with paclitaxel and carboplatin, respectively.

Keyphrases

small cell lung cancer
advanced non small cell lung cancer
metastatic colorectal cancer
high grade
adverse drug
brain metastases
drug induced
low grade
locally advanced
smoking cessation